Suppressing ZNF638 may improve glioblastoma immunotherapy

New research from the Sylvester Comprehensive Cancer Center suggests that suppressing a protein called ZNF638 can enhance the effectiveness of immune checkpoint inhibitors in treating glioblastoma, a challenging brain cancer. This discovery identifies ZNF638 as a potential biomarker for personalized immunotherapy. Glioblastoma, the most common brain tumor in adults, has seen little improvement in treatment outcomes over the past 20 years. The study indicates that targeting ZNF638 may create conditions that allow immune therapies to work better against this cancer. The findings show that patients with lower ZNF638 levels had better responses to immunotherapy. Researchers aim to develop a drug that targets ZNF638, which could improve treatment options for glioblastoma patients in the future.